| Autor: |
Maccagno M; Department of Molecular Biotechnology and Health Sciences, 10126 Turin, Italy.; Molecular Biotechnology Centre, University of Torino, 10126 Turin, Italy., Tapparo M; Molecular Biotechnology Centre, University of Torino, 10126 Turin, Italy.; Department of Medical Sciences, University of Torino, 10126 Turin, Italy., Saccu G; Molecular Biotechnology Centre, University of Torino, 10126 Turin, Italy.; Department of Medical Sciences, University of Torino, 10126 Turin, Italy., Rumiano L; Department of Molecular Biotechnology and Health Sciences, 10126 Turin, Italy.; Molecular Biotechnology Centre, University of Torino, 10126 Turin, Italy., Kholia S; Molecular Biotechnology Centre, University of Torino, 10126 Turin, Italy.; Department of Medical Sciences, University of Torino, 10126 Turin, Italy., Silengo L; Molecular Biotechnology Centre, University of Torino, 10126 Turin, Italy., Herrera Sanchez MB; Molecular Biotechnology Centre, University of Torino, 10126 Turin, Italy.; 2i3T, Società per la Gestione dell'incubatore di Imprese e per il Trasferimento Tecnologico, University of Torino, 10126 Turin, Italy. |
| Abstrakt: |
The rise in biological therapies has revolutionized oncology, with immunotherapy leading the charge through breakthroughs such as CAR-T cell therapy for melanoma and B-ALL. Modified bispecific antibodies and CAR-T cells are being developed to enhance their effectiveness further. However, CAR-T cell therapy currently relies on a costly ex vivo manufacturing process, necessitating alternative strategies to overcome this bottleneck. Targeted in vivo viral transduction offers a promising avenue but remains under-optimized. Additionally, novel approaches are emerging, such as in vivo vaccine boosting of CAR-T cells to strengthen the immune response against tumors, and dendritic cell-based vaccines are under investigation. Beyond CAR-T cells, mRNA therapeutics represent another promising avenue. Targeted delivery of DNA/RNA using lipid nanoparticles (LNPs) shows potential, as LNPs can be directed to T cells. Moreover, CRISPR editing has demonstrated the ability to precisely edit the genome, enhancing the effector function and persistence of synthetic T cells. Enveloped delivery vehicles packaging Cas9 directed to modified T cells offer a virus-free method for safe and effective molecule release. While this platform still relies on ex vivo transduction, using cells from healthy donors or induced pluripotent stem cells can reduce costs, simplify manufacturing, and expand treatment to patients with low-quality T cells. The use of allogeneic CAR-T cells in cancer has gained attraction for its potential to lower costs and broaden accessibility. This review emphasizes critical strategies for improving the selectivity and efficacy of immunotherapies, paving the way for a more targeted and successful fight against cancer. |
